Safety of Prothrombin Complex Concentrate for Emergency Surgery According to the Oral Factor Xa Inhibitor Level
Thrombosis and Haemostasis · 24.03.2026
DOI: 10.1055/a-2834-0030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 24.03.2026. Verfasst von Ali Eshaghpour und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Gefördert von: Octapharma.
Abstract (Originalsprache)
Background
Anti-Xa assays are seldom rapidly available, prompting clinicians to frequently administer four-factor-prothrombin complex concentrate (4F-PCC) empirically.
Objective
Determine if the thrombotic risk increases when preoperative factor Xa inhibitor (XaI) levels are low or unmeasured.
Methods
We analyzed retrospectively all patients who received 4F-PCC between September 2018 and July 2024 at five hospitals in the Hamilton region and screened for those with emergency surgery/invasive procedure as the main indication. The primary outcomes were symptomatic or asymptomatic, objectively verified arterial or venous thromboembolism within 7 days of 4F-PCC infusion. The secondary outcome was the same between postoperative days 8 and 30. XaI levels were determined with an anti-Xa assay, calibrated with the respective oral anticoagulant used by the patient.
Results
Four-F-PCC at a median dose of 2,000 units (interquartile range, 2,000–2,000) was administered to 227 patients on apixaban (143; 63%), rivaroxaban (72; 32%), or edoxaban (12;5%). The mean age was 76 years, and 42% were female. Prophylaxis against venous thromboembolism was started promptly in 214 patients (94%) after a median of 1 day (interquartile range, 1–2). Thromboembolism within 7 days occurred in 1 of 38 patients (3%) with high XaI level, 0 of 24 with low level, and 9 of 165 (5%) with no level.
Conclusion
The risk of thromboembolism after 4F-PCC in patients on XaI and emergency surgery/invasive procedures appears to be similar among patients with preoperative XaI levels that are high, low, or not measured. This information might be helpful in settings where rapid anti-Xa testing is unavailable.
Autor:innen und Institutionen
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, Ontario, Canada.
- Faculty of Science, McMaster University, Hamilton, Ontario, Canada.
- Department of Obstetrics and Gynecology and Perinatal Medicine, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia.
Förderung
- Octapharma
Zitieren
APA
Eshaghpour, A., Pai, M., Ibragimov, N., & Schulman, S. (2026). Safety of Prothrombin Complex Concentrate for Emergency Surgery According to the Oral Factor Xa Inhibitor Level. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2834-0030
Vancouver
Eshaghpour A, Pai M, Ibragimov N, Schulman S. Safety of Prothrombin Complex Concentrate for Emergency Surgery According to the Oral Factor Xa Inhibitor Level. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2834-0030
BibTeX
@article{Eshaghpour2026,
author = {Eshaghpour, Ali and Pai, Menaka and Ibragimov, Nicole and Schulman, Sam},
title = {Safety of Prothrombin Complex Concentrate for Emergency Surgery According to the Oral Factor Xa Inhibitor Level},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2834-0030}
}
EUVIMED